Ditch or Double Down on This Pharma ETF as Trump Adjusts Drug Prices?

The iShares U.S. Pharmaceuticals ETF (NYSEARCA:IHE) is the rare fund that has spent the past year being publicly threatened by the President of the United States and quietly outperforming nearly every healthcare benchmark anyway. Trump signed his “most favored nation” drug pricing executive order last May, tying what Medicare pays to lower prices in other developed countries, and IHE has since rallied 38% over twelve months to roughly $89. So the real question for retirement investors is whether IHE has already absorbed the policy hit, or whether the actual margin compression is still ahead of the ETF.

What IHE is built to do

IHE tracks the Dow Jones U.S. Select Pharmaceuticals Index, holding 59 names with charges of 0.38% a year. The return engine is straightforward. You collect dividends from a basket of mature U.S. drugmakers (the most recent quarterly distribution was $0.2845 per share) and you ride pipeline catalysts when blockbusters land. Eli Lilly (NYSE:LLY | LLY Price Prediction) and its tirzepatide franchise is the obvious one. AbbVie (NYSE:ABBV) and its immunology trio of Skyrizi, Rinvoq, and Humira are driving sales up significantly.

The catch is concentration. Johnson & Johnson and Eli Lilly together account for 42% of the fund, which means IHE is closer to a two-stock bet with 57 chaperones than a diversified pharma sleeve. Beta sits at 0.50, so volatility is genuinely lower than the broad market, but that statistic flatters the fund. When LLY moves on a GLP-1 data readout, IHE moves with it.

Does it actually deliver

The marketing pitch and the reality diverge in IHE’s favor. Over the past year, while Trump’s MFN order was being drafted, signed, and litigated, IHE returned 38%. The broader Health Care Select Sector SPDR, Health Care Select Sector SPDR Fund (NYSEARCA:XLV), returned 9% over the same window. Year-to-date in 2026, the gap is even more telling. IHE is up 4% while XLV is down 5%.

Step back to five and ten years, though, and the picture inverts. IHE is up 57% over five years and 128% over ten. XLV returned 29% over five and 149% over ten. Pure pharma lost to broad healthcare across a decade because device makers, insurers, and tools companies (the stuff XLV holds and IHE does not) carried the sector. The recent reversal is GLP-1 economics, plus pharma starting from depressed multiples after the 2024 selloff.

The tradeoffs that actually bite

1. Two-stock risk. If RFK Jr.’s HHS tightens GLP-1 labeling or Medicare negotiates Lilly’s tirzepatide aggressively, nearly half the fund reprices in a session. A 24/7 Wall St. analysis in March flagged this as the structural risk most IHE holders underestimate.
2. Policy overhang still looms. MFN was signed but implementation, court challenges, and the scope of covered drugs are unresolved. The market has priced an outcome while the actual rule remains unwritten.
3. Narrow scope by design. IHE owns mature cash flows and misses the AI-driven drug discovery story playing out at smaller names.

The verdict for retirement portfolios

The case for adding favors discipline over enthusiasm. If you already hold IHE as a healthcare allocation, the thesis (defensive cash flows, pipeline optionality, multiples still below the ten-year average) is working in real time. If you do not own pharma exposure and you are within ten years of retirement, IHE at $89 with a 0.50 beta fits the profile of a 5% to 8% sleeve. Investors who want the GLP-1 upside without 47% riding on two tickers have alternatives in VHT or XLV, accepting lower yield in exchange for diversification. Anyone treating IHE as a growth vehicle is reading the wrong fund.

In short, I would not double down. If you don’t hold it, I would add some exposure.